• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-Q/A filed by scPharmaceuticals Inc.

    12/31/24 6:04:00 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPH alert in real time by email
    10-Q/A
    trueQ30001604950--12-31 0001604950 2024-01-01 2024-09-30 0001604950 2024-11-12 0001604950 2024-07-01 2024-09-30 xbrli:shares
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    Form
    10-Q/A
     
     
    Amendment No. 1
     
    ☒
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the quarterly period ended September 30, 2024
    OR
     
    ☐
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from
     
     
      
     
    to
         
    Commission file number:
    001-38293
     
     
    SCPHARMACEUTICALS INC.
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware
     
    46-5184075
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification No.)
     
    25 Mall Road, Suite 203
     
    Burlington, Massachusetts
     
    01803
    (Address of principal executive office)
     
    (Zip Code)
    Registrant’s telephone number, including area code: (617)
    517-0730
    N/A
    (Former name, former address and former fiscal year, if changed since last report)
     
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
      
    Trading
    Symbol(s)
      
    Name of each exchange
    on which registered
    Common stock, par value $0.0001 per share
      
    SCPH
      
    The Nasdaq Global Select Market
    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
    S-T
    (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
    non-accelerated
    filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule
    12b-2
    of the Exchange Act.
     
    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated
    filer
      ☒    Smaller reporting company   ☒
    Emerging growth company   ☐     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
    Indicate by check mark whether the registrant is a shell company (as defined in Rule
    12b-2
    of the Exchange Act). Yes ☐ No  ☒
    As of November 12, 2024, the Registrant had 50,040,134 common shares, $0.0001 par value per share, outstanding.
     
     
     

    EXPLANATORY NOTE
    scPharmaceuticals Inc. (the “Company”) is filing this Amendment No. 1 on Form
    10-Q/A
    (this “Amendment”) to its Quarterly Report on Form
    10-Q
    for the quarterly period ended September 30, 2024, which was originally filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2024 (the “Original Filing”) to amend Part II “Item 5. Other Information” by adding disclosure regarding “Rule
    10b5-1
    trading arrangements” as defined in Item 408(a) of Regulation
    S-K
    that were entered into during the quarter ended September 30, 2024 by each of (i) John H. Tucker, the Company’s President and Chief Executive Officer and (ii) Rachael Nokes, the Company’s Chief Financial Officer.
    In addition, as required by Rule
    12b-15
    of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment, under Part II “Item 6. Exhibits” hereof, pursuant to Rule
    13a-14(a)
    or
    15d-14(a)
    of the Exchange Act. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation
    S-K,
    paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not including new certifications under Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (Section 906 of the Sarbanes-Oxley Act of 2002, as amended), as no financial statements are being filed with this Amendment. Other than as expressly set forth herein, this Amendment does not, and does not purport to, amend, update or restate the information in Original Filing or reflect any events that have occurred after the Original Filing was made. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original Filing was made. No changes have been made to the financial statements of the Company as contained in the Original Filing. Accordingly, this Amendment should be read together with the Original Filing and the Company’s other filings with the SEC.
    PART II - OTHER INFORMATION
    Item 5. Other Information
    (c) Insider Trading Arrangements and Policies.
    On August 20, 2024, John H. Tucker, the Company’s President and Chief Executive Officer, entered into a
    sell-to-cover
    instruction letter (the “Tucker Instruction Letter”) that provides for sales of only such number of shares of the Company’s common stock, $0.0001 par value (the “Common Stock”), as are necessary to satisfy the applicable tax withholding obligations arising exclusively from the vesting or settlement of restricted stock units (“RSUs”) granted to Mr. Tucker under the Company’s 2017 Stock Option and Incentive Plan, or any successor plan. The Tucker Instruction Letter is a “Rule
    10b5-1
    trading arrangement” as defined in Item 408(a) of Regulation
    S-K
    and is intended to satisfy the affirmative defense of Rule
    10b5-1(c).
    The Tucker Instruction Letter will remain in effect so long as taxes are required to be paid upon the vesting or settlement of RSUs awarded or to be awarded, unless the Tucker Instruction Letter is earlier terminated. The total number of shares of Common Stock that may be sold pursuant to the Tucker Instruction Letter is not determinable.
    On August 21, 2024, Rachael Nokes, the Company’s Chief Financial Officer, entered into a
    sell-to-cover
    instruction letter (the “Nokes Instruction Letter”) that provides for sales of only such number of shares of the Company’s Common Stock as are necessary to satisfy the applicable tax withholding obligations arising exclusively from the vesting or settlement of RSUs granted to Ms. Nokes under the Company’s 2017 Stock Option and Incentive Plan, or any successor plan. The Nokes Instruction Letter is a “Rule
    10b5-1
    trading arrangement” as defined in Item 408(a) of Regulation
    S-K
    and is intended to satisfy the affirmative defense of Rule
    10b5-1(c).
    The Nokes Instruction Letter will remain in effect so long as taxes are required to be paid upon the vesting or settlement of RSUs awarded or to be awarded, unless the Nokes Instruction Letter is earlier terminated. The total number of shares of Common Stock that may be sold pursuant to the Nokes Instruction Letter is not determinable.
    Other than as disclosed above, during the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a “Rule
    10b5-1
    trading arrangement” or
    “non-Rule
    10b5-1
    trading arrangement,” as each term is defined in Item 408(a) of Regulation
    S-K.

    Item 6. Exhibits
    EXHIBIT INDEX
     
    Exhibit
    Number
      
    Description
     31.1*    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     31.2*    Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    101*    Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form
    10-Q.
    104*    Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101*).
     
    *
    Filed herewith.

    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
       
    SCPHARMACEUTICALS INC.
    Date: December 31, 2024     By:  
    /s/ Rachael Nokes
          Rachael Nokes
         
    Chief Financial Officer
    (Principal Financial Officer)
    Get the next $SCPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPH

    DatePrice TargetRatingAnalyst
    9/7/2023$20.00Buy
    Craig Hallum
    12/1/2022$25.00Outperform
    Cowen
    10/21/2022$14.00Buy
    Jefferies
    10/11/2022$11.00Mkt Perform → Outperform
    SVB Leerink
    8/2/2022$10.00Buy
    Maxim Group
    9/9/2021$6.00Market Perform
    SVB Leerink
    More analyst ratings

    $SCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on scPharmaceuticals with a new price target

      Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00

      9/7/23 9:06:27 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on scPharmaceuticals with a new price target

      Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00

      12/1/22 7:54:00 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on scPharmaceuticals with a new price target

      Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00

      10/21/22 7:40:23 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: Wednesday, May 28, Investor Meetings OnlyH.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Presentation on May 20 at 10:00 a.m. ET. A webcast of the presentations

      5/1/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Orbimed Advisors Llc bought $2,000,000 worth of shares (500,000 units at $4.00) (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      8/15/24 4:51:14 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.

      SCHEDULE 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      4/28/25 4:01:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by scPharmaceuticals Inc.

      DEFA14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:12:38 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by scPharmaceuticals Inc.

      DEF 14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:10:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/15/24 4:06:50 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 5:48:35 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 3:58:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations

    $SCPH
    Financials

    Live finance-specific insights

    See more
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

      BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the

      3/12/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Tucker John H gave a grant of 200,000 shares, decreasing direct ownership by 31% to 440,847 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:32:59 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael was granted 88,445 shares, increasing direct ownership by 131% to 156,061 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:27:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael covered exercise/tax liability with 5,235 shares, decreasing direct ownership by 7% to 67,616 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      1/7/25 4:30:06 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

      Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

      10/11/22 1:54:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care